Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: A single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1272-1282

  Torkildsen, Gail L ^a,b   Abelson, Mark B ^a,b,c   Gomes, Paul J ^b  

^a Andover Eye Associates   (United States)

^b ORA Clinical Research and Development   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

allergic conjunctivitis; ketotifen fumarate; therapeutic bioequivalence

Indexed keywords

KETOTIFEN FUMARATE; PLACEBO;

ABDOMINAL PAIN; ABNORMAL SENSATION; ADULT; ALLERGIC CONJUNCTIVITIS; ARTHRALGIA; ARTICLE; BIOEQUIVALENCE; CHEMOSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; EAR INFECTION; FEMALE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OCULAR PRURITUS; PELVIS PAIN SYNDROME; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUS CONGESTION; SKIN TEST; SNEEZING; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ALLERGENS; ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KETOTIFEN; MALE; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; REFERENCE STANDARDS; THERAPEUTIC EQUIVALENCY;

EID: 48549101068     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80051-3     Document Type: Article

References (29)

1. Abelson M.B., Smith L., and Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocul Surf 1 (2003) 127-149
2. Allansmith M.R., and Ross R.N. Ocular allergy. Clin Allergy 18 (1988) 1-13
3. Abelson M.B., and Schaefer K. Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 38 (1993) 115-132
4. Kidd M., McKenzie S.H., Steven I., et al., for the Australian Ketotifen Study Group. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 87 (2003) 1206-1211
5. Abelson M.B., Chapin M.J., Kapik B.M., and Shams N.B. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol 121 (2003) 626-630
6. Abelson M.B., Ferzola N.J., McWhirter C.L., and Crampton H.J. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. Pediatr Allergy Immunol 15 (2004) 551-557
7. Greiner J.V., Mundorf T., Dubiner H., et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am J Ophthalmol 136 (2003) 1097-1105
8. Crampton H.J. A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin Ther 24 (2002) 1800-1808
9. US Dept of Health and Human Services, Food and Drug Administration. Approval of New Drug Application 21-066 (July 2, 1999), DHHS, Rockville, Md Letter
10. US Dept of Health and Human Services, Food and Drug Administration. Approval of Supplemental New Drug Application 21-066/S-011.
11. Letter (September 6, 2007). http://www.fda.gov/cder/foi/appletter/2006/021066s011ltr.pdf Accessed
12. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Application No. 21-066. Clinical Pharmacology and Biopharmaceutics Review.
13. (July 2, 2008). http://www.fda.gov/cder/foi/nda/99/21-066_ZADITOR%200.025%25_biopharmr.pdf Accessed
14. US Dept of Health and Human Services, Food and Drug Administration. Bioavailability and Bioequivalence Requirements. CFR §320.24.
15. (October 23, 2007). http://a257.g.akamaitech.net/7/257/2422/04nov20031500/edocket.access.gpo.gov/cfr_2003/aprqtr/pdf/21cfr320.24.pdf Accessed
16. Center for Drug Evaluation and Research, US Dept of Health and Human Services, Food and Drug Administration. Guidance Documents [FDA Web site].
17. (April 3, 2008). http://www.fda.gov/cder/guidance/index.htm Accessed
18. World Medical Association. Policy. WMA Declaration of Helsinki [WMA Web site].
19. (April 3, 2008). http://www.wma.net/e/policy/b3.htm Accessed
20. Abelson M., Chambers W.A., and Smith L.M. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 108 (1990) 84-88
21. Approval History, NDA 021066. 07/02/1999 Approval Label.
22. (July 2, 2008). http://www.fda.gov/cder/foi/label/1999/21066lbl.pdf Accessed
23. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
24. Kabra S.K., Pandey R.M., Singh R., and Seth V. Ketotifen for asthma in children aged 5 to 15 years: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 85 (2000) 46-52
25. Magnussen H. The inhibitory effect of azelastine and ketotifen on histamine-induced bronchoconstriction in asthmatic patients. Chest 91 (1987) 855-858
26. Tinkelman D.G., Moss B.A., Bukantz S.C., et al. A multicenter trial of the prophylactic effect of ketotifen, theophylline, and placebo in atopic asthma. J Allergy Clin Immunol 76 (1985) 487-497
27. Soparkar C.N., Wilhelmus K.R., Koch D.D., et al. Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants. Arch Ophthalmol 115 (1997) 34-38
28. Schenker H., Maloney S., Liss C., et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther 21 (1999) 138-147
29. Stewart W.C., Konstas A.G., and Pfeiffer N. nPatient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 20 (2004) 461-469